CLINICAL TRIALS PROFILE FOR DIOVAN HCT

All Clinical Trials for DIOVAN HCT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	Bayer	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	GlaxoSmithKline	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	Boehringer Ingelheim	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00130156 ↗	Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension	Completed	Eisai Co., Ltd.	Phase 4	2005-10-01	The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome.

Clinical Trial Conditions for DIOVAN HCT

Condition Name

Condition Name for DIOVAN HCT
Intervention	Trials
Hypertension	22
High Blood Pressure	3
Essential Hypertension	2
Hyperlipidemia	2

Condition MeSH

Condition MeSH for DIOVAN HCT
Intervention	Trials
Hypertension	25
Essential Hypertension	6
Diabetes Mellitus	6
Diabetes Mellitus, Type 2	5

Clinical Trial Locations for DIOVAN HCT

Trials by Country

Trials by Country for DIOVAN HCT
Location	Trials
United States	155
Korea, Republic of	10
China	8
Canada	7
Japan	6

Trials by US State

Trials by US State for DIOVAN HCT
Location	Trials
Pennsylvania	7
Maryland	7
New York	7
Texas	6
Missouri	6

Clinical Trial Progress for DIOVAN HCT

Clinical Trial Phase

Clinical Trial Phase for DIOVAN HCT
Clinical Trial Phase	Trials
Phase 4	25
Phase 3	10
Phase 2	3

Clinical Trial Status

Clinical Trial Status for DIOVAN HCT
Clinical Trial Phase	Trials
Completed	31
Terminated	6
Unknown status	6

Clinical Trial Sponsors for DIOVAN HCT

Sponsor Name

Sponsor Name for DIOVAN HCT
Sponsor	Trials
Novartis	7
Boryung Pharmaceutical Co., Ltd	4
Novartis Pharmaceuticals	4

Sponsor Type

Sponsor Type for DIOVAN HCT
Sponsor	Trials
Other	65
Industry	35
NIH	4